Format

Send to

Choose Destination
See comment in PubMed Commons below
Lung Cancer. 2016 Dec;102:136-138. doi: 10.1016/j.lungcan.2016.07.012. Epub 2016 Jul 14.

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.

Author information

1
Department of Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland. Electronic address: ioannis.metaxas@ksgr.ch.
2
Department of Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland.

Abstract

Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. At progression it is possible to provide systemic second-line treatment but its effects are limited. Herein we report two patient cases with mesothelioma who received second-line chemotherapy with the combination of cisplatin and the novel compound lurbinectedin. The combination showed promising activity in both cases with manageable toxicity. We discuss the results of this regime in the light of historical as well as emerging data in mesothelioma.

KEYWORDS:

Lurbinectedin; Mesothelioma; Palliative chemotherapy

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center